Harrow Health, Inc. (HROW) intrinsic value snapshot: our valuation models currently suggest the stock is overvalued, with an estimated 107.4% downside relative to fair value at a market price of $42.48. The dollar intrinsic value (fair value) for Harrow Health, Inc. is derived from DCF, P/E Multiple, and P/S Multiple models—available with Tickerplace Pro for investors comparing market price to modeled fair value.
How we calculate fair value: We combine DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models to estimate intrinsic value. This figure is for information only - not investment advice - and assumptions may not reflect actual market conditions. We encourage doing your own research or speaking with a financial advisor before making investment decisions.
Intrinsic Value checker
Search our company database (same as the site header), pick a match, or type a ticker to open its intrinsic value analysis.
Is Harrow Health, Inc. (HROW) undervalued or overvalued?
Based on our intrinsic value models, Harrow Health, Inc. (HROW) currently looks overvalued with an estimated 107.37% downside relative to fair value at $42.48. Sign in to Tickerplace Pro to view the full dollar fair value estimate and margin of safety.
Fair value vs market price — Harrow Health, Inc. (HROW)
Harrow Health, Inc. (HROW) fair value vs market price: our valuation models suggest overvalued positioning with an estimated 107.4% downside relative to intrinsic value at a market price of $42.48. The dollar fair value for Harrow Health, Inc. is calculated from DCF, P/E Multiple, and P/S Multiple models—available with Tickerplace Pro for a full market-price-to-fair-value breakdown and margin of safety.
What is the intrinsic value of Harrow Health, Inc. (HROW)?
Our models calculate the intrinsic value of Harrow Health, Inc. (HROW) using DCF, P/E Multiple, and P/S Multiple approaches based on projected cash flows, growth rate, and discount rate. Sign in to Tickerplace Pro to view the full dollar estimate.
Is HROW undervalued or overvalued?
Based on our 2026 valuation models, HROW appears overvalued at its current price of $42.48. Our model suggests the stock may be overvalued by 107.4%.
How is HROW's intrinsic value calculated?
Tickerplace calculates HROW's intrinsic value using Discounted Cash Flow (DCF), P/E Multiple, and P/S Multiple models. We project future cash flows, apply a discount rate that reflects investment risk, and compare the resulting fair value estimate to the current market price.